▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1256 by analyst upside · 2026-09-28
ENGN
enGene Therapeutics Inc.
Healthcare · Market Cap $131M · P/E 0x
ANALYST PRICE TARGET
+67.6%
implied upside to consensus target
Current Price $1.96
Consensus Target $3.29
Bull Target $5.0
Bear Target $2.0
Analysts Covering 7
ANALYST CONSENSUS - HOLD
Strong Buy
1
Buy
1
Hold
4
Sell
1
52-Week Low $1.4
52-Week High $12.25
YTD Return -77.9%
FUNDAMENTALS
Market Cap $131M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-2.07
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.4
52-Week High $12.25
Current Price $1.96
Bear Target $2.0
Bull Target $5.0
● Now $1.96 ● Target $3.29
TRADING DATA
Avg Volume 814K
YTD Return -77.9%
Analyst Count 7
Consensus Hold
Upside to Target +67.6%
Last Updated 2026-09-28

ANALYST SUMMARY

enGene Therapeutics Inc. (ENGN) is currently trading at $1.96 with a Wall Street consensus price target of $3.29, implying potential upside of 67.6% over the next 12 months. 7 analysts currently cover ENGN, with a consensus rating of Hold - 29% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $5.0, while the most cautious has a target of $2.0.

ENGN operates in the Healthcare sector with a market capitalisation of $131M. The stock is down 77.9% year-to-date and is currently trading near the lower end of its 52-week range of $1.4 – $12.25.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

WW +97.4%
WW International, Inc.
$144M · P/E 1.6x · Hold
ORMP +48.0%
Oramed Pharmaceuticals Inc.
$197M · P/E 1.1x · Hold
BSEM +69.1%
BioStem Technologies, Inc.
$74M · P/E 4.7x · Buy
CGEN +93.3%
Compugen Ltd.
$225M · P/E 6.3x · Buy
OPRX +54.2%
OptimizeRx Corporation
$151M · P/E 32.2x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for ENGN, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Citizens reit
Market Perform → Market Perform 2026-09-09 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-09-08 31% win rate (48 calls)
Morgan Stanley ↓ Downgrade
Equal-Weight → Underweight 2026-06-18 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-06-16 31% win rate (48 calls)
UBS - Reiterated
Neutral → Neutral 2026-05-14 33% win rate (6 calls)
Citizens ↓ Downgrade
Market Outperform → Market Perform 2026-05-08 Building track record
Guggenheim ↓ Downgrade
Buy → Neutral 2026-05-08 62% win rate (8 calls)
Wells Fargo ↓ Downgrade
Overweight → Equal-Weight 2026-05-08 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
18
out of 100
Coverage depth
16/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →